Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc. (OTC: PKBO), a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX.
Read the full article: Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge //
Source: https://www.globenewswire.com/news-release/2024/03/05/2840389/0/en/Akari-Therapeutics-and-Peak-Bio-Announce-Definitive-Agreement-to-Merge-as-Equals-Creating-an-Expanded-Pipeline-That-Features-a-Novel-Antibody-Drug-Conjugate-ADC-Toolkit.html